Bacitracin enhances intracellular accumulation of insulin in rat adipocytes.
Bacitracin (1 mg/ml) markedly increased (approx. 75%) the cell-associated specifically bound 125I-labelled insulin without altering the affinity of the binding sites. Bacitracin also exerted a modest inhibitory effect on the degradation of insulin in the incubation medium determined as radioactivity not precipitated by trichloroacetic acid (from 9.6 to 4.8%). The effect on insulin binding was about 5-times as sensitive as the effect on degradation. The increased binding was due to intracellular accumulation of radioactivity which could not be removed by treating the cells with trypsin. This increase was not seen when the internalization process was reduced by ATP-depletion or low temperature. Since the trypsin-sensitive fraction of cell-associated radioactivity was apparently not altered, it is suggested that bacitracin, in addition to its well-known inhibition of extracellular degradation, also inhibits the intracellular degradation of insulin.
D019325:3-O-Methylglucose; D000255:Adenosine Triphosphate / Q000494:pharmacology; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D001414:Bacitracin / Q000494:pharmacology*; D002738:Chloroquine / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism*; D008297:Male; D008757:Methylglucosides / Q000378:metabolism; D051381:Rats; D014357:Trypsin / Q000494:pharmacology
D007328:Insulin; D008757:Methylglucosides; D001414:Bacitracin; D019325:3-O-Methylglucose; D002738:Chloroquine; D000255:Adenosine Triphosphate; D014357:Trypsin